Boehringer Ingelheim reports survodutide meets cardiovascular safety endpoint

Key highlights
  • The trial met its primary endpoint: 5P-MACE risk was not increased versus placebo (HR 0.89; 95% CI 0.67–1.18).
  • At week 72, weight loss reached 13.7% and waist circumference fell by up to 11.96 cm, using the supplementary secondary estimand.
  • Systolic blood pressure fell by up to 6.68 mmHg at week 72, compared with 1.76 mmHg with placebo.
  • GI-related discontinuations occurred in 19.3% and 20.8% of participants on 3.6 mg and 6.0 mg doses, respectively, versus 1.9% on placebo.

Cardiovascular outcomes

Boehringer Ingelheim reported that the Phase III SYNCHRONIZE-CVOT trial met its primary endpoint. In adults with obesity or overweight and elevated cardiovascular risk, survodutide did not increase the risk of 5P-MACE versus placebo (HR 0.89; 95% CI 0.67–1.18), meeting the non-inferiority criterion. The trial also found no increased risk of 3P-MACE (HR 0.84; 95% CI 0.60–1.18).

Cardiometabolic measures and tolerability

At week 72, results using the supplementary secondary estimand showed weight loss of up to 13.7%, compared with 2.0% for placebo; waist circumference reduction of up to 11.96 cm, compared with 2.74 cm; and systolic blood pressure reduction of up to 6.68 mmHg, compared with 1.76 mmHg. The trial also reported reductions in hs-CRP and triglycerides.

The most commonly reported adverse events were gastrointestinal, including nausea, vomiting, diarrhea and constipation, mostly mild to moderate. Discontinuation due to GI events was 19.3% with 3.6 mg and 20.8% with 6.0 mg, versus 1.9% with placebo. Boehringer Ingelheim said the trial protocol allowed limited flexibility for managing adverse events during dose escalation.

Development plans

Survodutide is an investigational glucagon/GLP-1 dual receptor agonist and has not been approved; its efficacy and safety have not been established. The company said it is moving forward with global regulatory submissions in obesity. Further trials are investigating its use in obesity, type 2 diabetes and MASH.

Source: Boehringer Ingelheim

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

1 October 2026
Boehringer Ingelheim reports Phase III survodutide results in obesity and type 2 diabetes

At 76 weeks, weight loss reached 13.1%, HbA1c fell by up to 1.21%, and gastrointestinal events led 18% of treated participants to discontinue.

7 June 2026
Boehringer Ingelheim: Survodutide Phase III shows up to 34% visceral and 63% liver fat reduction with limited lean mass loss

Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.

12 November 2026
Lilly starts construction of $3.5bn obesity-medicine plant in Pennsylvania

The Fogelsville facility will make injectable medicines, including investigational retatrutide, and is expected to be operational by 2031.

9 November 2026
Merck reports positive Phase 2b efinopegdutide data in MASH with F2–F3 fibrosis

Efinopegdutide achieved higher rates of MASH resolution and meaningful fibrosis improvement versus placebo at 52 weeks, with a safety profile broadly similar to semaglutide.

5 November 2026
Lilly showcases retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026

Phase 3 TRIUMPH trials showed retatrutide cut knee pain by up to 75.8% with some patients pain‑free; TOGETHER‑PsA found ixekizumab plus tirzepatide raised ACR50 to 43.7% at 52 weeks.